Clematis chinensis Extract Protects against Diabetic Nephropathy in Rats
Abstract
Purpose: To study the effect of Clematis chinensis extract (CCE) on diabetic nephropathy in rats.
Methods: Eight-week old male Wistar rats were injected with streptozotocin to induce diabetes. The effects of CCE(250 or 500 mg/kg) on renal function index, fasting blood glucose (FBG), blood fat, oxidation index, and pathological kidney changes for 3 weeks were compared to those of the positive control drug, captopril.
Results: At 12 weeks, CCE(500 mg/kg) treatment had significantly decreased serum blood urea nitrogen (BUN, 12.61 ± 1.42 mmol/L), serum creatinine (SCr, 84.64 ± 6.37 μmol/L), creatinine clearance (CCr, 0.88 ± 0.10 mmol/L), interleukin-6 (IL-6, 297.56 ± 19.62 pg/mL), urinary albumin, urinary albumin excretion rate (UAER, 11.68 ± 0.97 μg/min), kidney hypertrophy index (kidney weight/body weight, 0.58 ± 0.03%) and FBG (11.51 ± 0.96 mmol·L-1). It significantly decreased triglyceride (TG, 0.26 ± 0.05 mmol/L), total cholesterol (TC, 1.52 ± 0.06 mmol/L) and low-density lipoprotein cholesterol (LDL-c, 0.71 ± 0.06 mmol/L) levels and increased high density lipoprotein-cholesterol (HDL-c, 0.65 ± 0.05 mmol/L). CCE treatment also significantly decreased malondialdehyde (MDA, 16.14 ± 1.24 nmol/mgprot) levels and increased superoxide dismutase (SOD, 95.17 ± 4.06 U/mgprot) and glutathione peroxidase (GSHPx, 154.33 ± 11.76 mmol/L) (both p < 0.05). Finally, CCE reduced the degree of glomerular basement membrane and renal tubular thickening and swelling in diabetic rats.
Conclusion: CCE has a significant inhibitory effect on diabetic nephropathy-induced renal injury in rats.
Keywords: Clematis chinensis, Diabetic nephropathy, Renal function, Pathological morphology
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
